← Back to Newsletter Archive

Greetings!

Welcome to the QPS Pharmacology Newsletter


Discover more about the Chronic DSS-induced ulcerative colitis pharmacology model, take a closer look at better metabolite insights for oligonucleotide development, and stay ahead of the curve with the latest scientific breakthroughs on the QPS blog.

Chronic Dextran Sulphate Sodium-induced Ulcerative Colitis Model

Advance your ulcerative colitis (UC) research with the QPS chronic DSS-induced colitis model, a widely used murine model for evaluating the therapeutic effects of new test articles.


Using three controlled cycles of DSS administration and recovery, this model provides a structured approach for assessing potential treatments for chronic UC.

Discover More Pharmacology Models at QPS

Unlocking Oligonucleotide Met-ID Secrets

Progress your therapeutic oligonucleotide program with a clearer understanding of drug metabolism identification.


Discover how advanced LC/HRMS techniques can identify, profile, and quantify metabolites while addressing evolving analytical and regulatory challenges.


Download the white paper to discover strategies that can strengthen your bioanalytical approach and support confident development decisions.

Download the White Paper

Therapeutic Oligo Met-ID, Profiling and Quantitation

Discover the Future of Science on the QPS Blog

Stopping Genetic Expansion Could Transform Huntington’s Disease and More



For years, drug development for Huntington’s disease has focused on reducing the toxic huntingtin protein produced by the mutant HTT gene. That strategy remains…


A New Development Strategy Takes Shape

Gene Therapy at QPS

Disarming the Gut Toxin Behind Colon Cancer


Colorectal cancer is a stealthy killer, causing as many as 900,000 deaths each year, per the most recent World Health Organization data. As the…


Leveraging the Findings for a Cancer-Prevention Drug

Oncology Clinical Trials at QPS

Contact the Experts at QPS


Request a meeting with QPS preclinical, bioanalysis, translational medicine, and/or clinical research subject matter experts today to explore how we can help accelerate your next drug development program.

Visit our website www.qps.com 

or contact us at infopr@qps.com

to start your next study.

 
Linkedin  Youtube  X  Facebook  

View as Webpage

www.qps.com | infopr@qps.com

We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)
← Back to Newsletter Archive